VivoSeq
Other

Imaging

0

Pipeline Programs↗

65

Active Trials↗

22

Companies Involved↗

Imaging is an early-stage landscape with 0 programs across 22 companies. The most active players are Avid Radiopharmaceuticals, GSK, Navidea Biopharmaceuticals.

Intelligence

Pipeline Metrics

Competitive Density

53/100

Pipeline Velocity

45/100

Mech. Concentration

N/A

Completion Rate

78/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Avid Radiopharmaceuticals

0 programs

PreclinicalGSK logo

GSK

0 programs

PreclinicalN

Navidea Biopharmaceuticals

0 programs

PreclinicalLundbeck logo

Lundbeck

0 programs

PreclinicalAstellas logo

Astellas

0 programs

PreclinicalS

Sinotau Pharmaceutical Group

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

250

clinical trials

Completed125 · 50%
Recruiting50 · 20%
Terminated25 · 10%
Unknown status24 · 10%
Withdrawn9 · 4%
Active, not recruiting7 · 3%
Other10 · 4%

Clinical Trials

Trial Activity

250 trials

Imaging Immune Activation in HIV by PET-MR
Recruiting·CCellSight Technologies, Inc.·Phase 2·NCT03684655·30 enrolled
CD70-targeted immunoPET Imaging of Malignant Cancers
Recruiting·RRenJi Hospital·N/A·NCT06852638·300 enrolled
Cerebellum-based Imaging Neural Markers for Antipsychotic Response
Recruiting·NNorthwell Health·N/A·NCT07483294·120 enrolled
PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620
Recruiting·UUniversity of Pennsylvania·Phase 3·NCT05456503·72 enrolled
First-in-Human Assessment of Safety, Biodistribution and Pharmacokinetics of 18F-Fluoro-1-Naphthol (18F-4FN) for PET Imaging
Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT05335811·55 enrolled
Multimodal Brain Imaging of the Neural Effects of Methylphenidate in Patients With ADHD
Recruiting·JJohns Hopkins University·Phase 4·NCT04781972·30 enrolled
PET Imaging Study of 64Cu-GRIP B for Patients Receiving CD19-directed CAR-T Therapy
Recruiting·—·Phase 1·NCT06522932·32 enrolled
18F-DOPA II - PET Imaging Optimization
Recruiting·UUniversity of Alberta·Phase 3·NCT04706910·800 enrolled
129 Xenon Imaging in Patients Treated With Sotatercept
Recruiting·—·Phase 2·NCT06351345·14 enrolled
68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors
Recruiting·UUniversity of Alberta·Phase 2·NCT04888481·600 enrolled
RESTORE Imaging: an OCT-IVUS Imaging Substudy of RESTORE Trial
Recruiting·HHarbin Medical University·N/A·NCT06449274·180 enrolled
Hyperpolarized MR Imaging with Carbon-13 Pyruvate in the Human Body
Recruiting·National Heart Centre Singapore·Phase 2·NCT06645691·200 enrolled
Ultralow Dose PET Imaging of 18F-Florbetapir, 18F-Flutemetamol
Recruiting·—·Phase 2·NCT07012993·200 enrolled
Imaging Synapses With [11C] UCB-J in the Human Brain
Recruiting·—·Phase 1·NCT04038840·60 enrolled
Ultralow Dose PET Imaging of 18F-FDG Uptake
Recruiting·—·Phase 2·NCT06956391·200 enrolled
Page 1 of 17

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)